Table 2. TAUR treatment improves cardiac function after MI.

Group	Vehicle-sham (n=6)	TAUR-sham (n=6)	Vehicle-MI (n=6)	TAUR-MI (n=6)
EF	75.95±8.31	65.08±6.84	43.44±7.86*	55.93±4.28†
FS	44.66±7.96	35.27±5.27	21.62±4.55*	29.17±2.76†
IVSd	1.43±0.12	1.53±0.26	1.08±0.13*	1.06±0.23
IVSs	0.83±0.10	0.97±0.14	0.73±0.08*	0.70±0.12
LVIDd	3.78±0.51	3.74±0.43	4.86±0.46*	4.62±0.32
LVIDs	2.10±0.47	2.42±0.37	3.81±0.48*	3.27±0.31†
LVPWd	0.75±0.13	0.81±0.10	0.72±0.09	0.78±0.16
LVPWs	1.37±0.30	1.16±0.17	0.94±0.11*	1.02±0.24
LV Mass	105.43±14.97	123.47±27.68	144.65±32.79	138.56±39.78
LV VOLd	62.68±20.81	60.86±16.08	111.92±24.5*	98.82±16.51
LV VOLs	15.55±8.14	21.47±8.29	64.00±19.1*	43.88±9.71
HR	504±50	474±40	449±42	459±43

EF, ejection fraction; FS, fractional shortening; IVSs, interventricular septum wall thickness in end-systole; IVSd, interventricular septum wall thickness in end-diastole; LVIDd, left ventricle end-diastolic inner diameter; LVIDs, left ventricle end-systolic inner diameter; LVPWs, left ventricle posterior wall thickness in end-systole; LVPWd, left ventricle posterior wall thickness in end-diastole; LV VOLd, LV volumes at end-diastole; LV VOLs, LV volumes at end-systole; HR, heart rate. Data are presented as mean ± SD, n=6 per group. *, P<0.05 versus corresponding sham group; ^†, P<0.05 versus vehicle-MI group.